he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images


September 29, 2020 — On Sept. 18, 2020, the Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule. The final rule includes a mandatory radiation oncology (RO) Model and End-Stage Renal Disease Treatment Choices Model. CMS believes these models will further their goal of shifting away from payment for volume of services alone and toward paying for value and outcomes. The RO Model will qualify as an advanced alternative payment model under the Quality Payment Program.

The RO Model will begin Jan. 1, 2021 and will run through Dec. 31, 2025. Certain radiation therapy (RT) providers and RT suppliers that furnish RT services within randomly selected Core Based Statistical Areas (geographic areas determined by zip code) are required to participate in the RO Model. The RO Model will include 30% of RO episodes in eligible geographic areas. The list of mandatory participants can be found on the RO Model website under “Participating Zip Code List.”

Under the RO Model, Medicare will pay participating providers and suppliers a prospective, site-neutral, episode-based payment for specified technical and professional RT services furnished during a 90-day episode to Medicare fee-for-service beneficiaries diagnosed with 16 different cancer types. An episode will only be triggered if there is an initial treatment planning service and at least one radiation treatment service within 28 days. Furthermore, another episode may not be triggered until at least 28 days after the previous episode has ended, referred to as the “clean period.” The base payment amounts for RT services included in the model will be the same for hospital outpatient departments and freestanding radiation therapy centers.

The American College of Radiology (ACR) will join the American Society for Radiation Oncology (ASTRO) in urging CMS and Congress to significantly delay the start date of the RO Model. Despite recommendations from ASTRO and the ACR to allow providers at least six months from the publication of the final rule to implementation due to the impacts of the COVID-19 public health emergency, CMS’ final rule only allows providers three and a half months to prepare for implementation. On Sept. 18, ASTRO issued a statement calling for additional reforms to the model along with delay in implementation. ASTRO stated that although mandatory participation representing 30% of eligible RO episodes is a positive step from the proposed 40%, this final rule goes too far for an untested model. The ACR strongly supports ASTRO’s statement and will be partnering in advocacy efforts.

Read the ACR initial summary on the model.

Related Radiation Oncology Content:

ASTRO responds to CMS Radiation Oncology Model


Related Content

News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Therapy

April 12, 2024 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery, and ...

Time April 12, 2024
arrow
News | Artificial Intelligence

April 9, 2024 —PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for ...

Time April 09, 2024
arrow
News | Artificial Intelligence

April 8, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time April 08, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a snapshot of the Top 10 most-read content from ITN's viewers during the month of March: 1. Philips Teams with ...

Time April 04, 2024
arrow
Subscribe Now